162 related articles for article (PubMed ID: 34147283)
1. Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
Jiang C; Li Z
Gynecol Oncol; 2021 Aug; 162(2):339-344. PubMed ID: 34147283
[TBL] [Abstract][Full Text] [Related]
2. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
[TBL] [Abstract][Full Text] [Related]
3. Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer.
Narasimhulu DM; Fagotti A; Scambia G; Weaver AL; McGree M; Quagliozzi L; Langstraat C; Kumar A; Cliby W
Int J Gynecol Cancer; 2023 Jan; 33(1):83-88. PubMed ID: 36517075
[TBL] [Abstract][Full Text] [Related]
4. Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
Narasimhulu DM; Kumar A; Weaver AL; Langstraat CL; Cliby WA
Gynecol Oncol; 2020 Jun; 157(3):572-577. PubMed ID: 32247602
[TBL] [Abstract][Full Text] [Related]
5. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
8. Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.
Narasimhulu DM; Thannickal A; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2021 Mar; 160(3):681-687. PubMed ID: 33390326
[TBL] [Abstract][Full Text] [Related]
9. A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study.
Feng Z; Wen H; Jiang Z; Liu S; Ju X; Chen X; Xia L; Xu J; Bi R; Wu X
J Gynecol Oncol; 2018 Sep; 29(5):e65. PubMed ID: 30022629
[TBL] [Abstract][Full Text] [Related]
10. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
13. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Boerner T; Filippova OT; Chi AJ; Iasonos A; Zhou QC; Long Roche K; Zivanovic O; Park BJ; Huang J; Jones DR; Abu-Rustum NR; Gardner G; Sonoda Y; Chi DS
Gynecol Oncol; 2020 Oct; 159(1):66-71. PubMed ID: 32792282
[TBL] [Abstract][Full Text] [Related]
14. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
15. Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS; van Driel WJ; van Ham M; Wouters MW; Kruitwagen R;
Gynecol Oncol; 2021 Aug; 162(2):331-338. PubMed ID: 34147284
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
17. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
18. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
19. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Cybulska P; Avery L; May T; Hogen L
Gynecol Oncol; 2022 Sep; 166(3):453-459. PubMed ID: 35820987
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
Xu Y; Jia Y; Zhang Q; Du Y; He Y; Zheng A
Gynecol Oncol; 2021 Feb; 160(2):610-618. PubMed ID: 33221022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
